EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieOpen Access

Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years

Amanda K Rudman Spergel, Iris Wu, Weiping Deng, Jose Cardona, Kimball Johnson, Ivette Espinosa-Fernandez, Melissa Sinkiewicz, Veronica Urdaneta, Lizbeth Carmona, Kristin Schaefers, Bethany Girard, Yamuna D Paila und 7 weitere

JAMA · 10.06.2025 · 333 (22) · 1977

DOI: 10.1001/jama.2025.5646 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 10.06.2025. Verfasst von Amanda K Rudman Spergel und 18 weiteren Autor:innen. Beteiligte Einrichtung: Moderna Inc, Cambridge, Massachusetts. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine, Influenza Vaccines. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Uptake of recommended seasonal influenza and COVID-19 vaccines remains suboptimal.

Objective

To assess the immunogenicity and safety of an investigational mRNA-1083 vaccine against seasonal influenza and SARS-CoV-2 in adults 50 years and older. Design, Setting, and Participants This phase 3, randomized, observer-blinded trial was conducted across 146 US sites in adults 50 years and older enrolled between October 19, 2023, and November 21, 2023. Data extraction was complete on April 9, 2024.

Interventions

Participants in 2 age cohorts (≥65 years and 50-64 years) were randomly assigned (1:1) to receive mRNA-1083 plus placebo or coadministered licensed quadrivalent seasonal influenza (≥65 years: high-dose quadrivalent inactivated influenza vaccine [HD-IIV4]; 50-64 years: standard-dose IIV4 [SD-IIV4]) and COVID-19 (all ages: mRNA-1273) vaccines. Main Outcomes and Measures The primary objectives were to demonstrate the noninferiority of humoral immune responses following mRNA-1083 vs comparators against vaccine-matched strains at day 29 and to evaluate the reactogenicity and safety of mRNA-1083. Secondary objectives included demonstration of superiority of humoral immune responses elicited by mRNA-1083 relative to comparators at day 29.

Results

Overall, 8015 participants were enrolled and vaccinated (4017 aged ≥65 y and 3998 aged 50-64 y). Among adults 65 years and older and 50 to 64 years, the median age was 70 and 58 years, 54.2% and 58.8% were female, 18.4% and 26.7% were Black or African American, and 13.9% and 19.3% were Hispanic or Latino, respectively. Noninferior immunogenicity of mRNA-1083 was demonstrated against all vaccine-matched influenza and SARS-CoV-2 strains based on lower bound of the 97.5% CI of the geometric mean ratio greater than 0.667 and lower bound of the 97.5% CI of the seroconversion/seroresponse rate difference greater than −10%. mRNA-1083 elicited higher immune responses than SD-IIV4 (50-64 years) for all 4 influenza strains and HD-IIV4 (≥65 years) for 3 influenza strains (A/H1N1, A/H3N2, B/Victoria) and against SARS-CoV-2 (all ages). Solicited adverse reactions were numerically higher in frequency and severity after mRNA-1083 vaccination than comparators in both age cohorts (≥65 y: 83.5% and 78.1%; 50-64 y: 85.2% and 81.8%); most were grade 1 or 2 in severity and of short duration. No safety concerns were identified. Conclusions and Relevance In this study, mRNA-1083 met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64 y), the 3 clinically relevant influenza strains (among those aged ≥65 y), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT06097273

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesImmunogenicity, VaccineInfluenza VaccinesInfluenza, HumanVaccines, CombinedAgedFemaleHumansMaleMiddle Aged2019-nCoV Vaccine mRNA-1273Antibodies, ViralSARS-CoV-2Vaccines, InactivatedInfluenza B virusInfluenza A virus

Substanzen

2019-nCoV Vaccine mRNA-1273Antibodies, ViralCOVID-19 VaccinesInfluenza VaccinesVaccines, InactivatedVaccines, Combined

Autor:innen und Institutionen

  • Moderna Inc, Cambridge, Massachusetts.
  • Indago Research and Health Center, Hialeah, Florida.
  • CenExel iResearch, Decatur, Georgia.
  • Revival Research Corporation, Doral, Florida.

Zitieren

APA

Rudman Spergel, A. K., Wu, I., Deng, W., Cardona, J., Johnson, K., Espinosa-Fernandez, I., Sinkiewicz, M., Urdaneta, V., Carmona, L., Schaefers, K., Girard, B., Paila, Y. D., Mehta, D., Callendret, B., Kostanyan, L., Ananworanich, J., Miller, J., Das, R., & Shaw, C. A. (2025). Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years. JAMA, 333(22), 1977. https://doi.org/10.1001/jama.2025.5646

Vancouver

Rudman Spergel AK, Wu I, Deng W, Cardona J, Johnson K, Espinosa-Fernandez I, et al. Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years. JAMA. 2025;333(22):1977. doi:10.1001/jama.2025.5646

BibTeX
@article{RudmanSpergel2025,
  author = {Rudman Spergel, Amanda K and Wu, Iris and Deng, Weiping and Cardona, Jose and Johnson, Kimball and Espinosa-Fernandez, Ivette and Sinkiewicz, Melissa and Urdaneta, Veronica and Carmona, Lizbeth and Schaefers, Kristin and Girard, Bethany and Paila, Yamuna D and Mehta, Darshan and Callendret, Benoit and Kostanyan, Lusine and Ananworanich, Jintanat and Miller, Jacqueline and Das, Rituparna and Shaw, Christine A},
  title = {Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {22},
  pages = {1977},
  doi = {10.1001/jama.2025.5646}
}
Kostenlos starten →